Literature DB >> 16123767

The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia.

Garry D Honey1, Chris O'loughlin, Danielle C Turner, Edith Pomarol-Clotet, Philip R Corlett, Paul C Fletcher.   

Abstract

Ketamine is increasingly used to model the cognitive deficits and symptoms of schizophrenia. We investigated the extent to which ketamine administration in healthy volunteers reproduces the deficits in episodic recognition memory and agency source monitoring reported in schizophrenia. Intravenous infusions of placebo or 100 ng/ml ketamine were administered to 12 healthy volunteers in a double-blind, placebo-controlled, randomized, within-subjects study. In response to presented words, the subject or experimenter performed a deep or shallow encoding task, providing a 2(drug) x 2(depth of processing) x 2(agency) factorial design. At test, subjects discriminated old/new words, and recalled the sources (task and agent). Data were analyzed using multinomial modelling to identify item recognition, source memory for agency and task, and guessing biases. Under ketamine, item recognition and cued recall of deeply encoded items were impaired, replicating previous findings. In contrast to schizophrenia, there was a reduced tendency to externalize agency source guessing biases under ketamine. While the recognition memory deficit observed with ketamine is consistent with previous work and with schizophrenia, the changes in source memory differ from those reported in schizophrenic patients. This difference may account for the pattern of psychopathology induced by ketamine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16123767      PMCID: PMC3838935          DOI: 10.1038/sj.npp.1300846

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Reality discrimination, reality monitoring and disposition towards hallucination.

Authors:  P M Rankin; P J O'Carroll
Journal:  Br J Clin Psychol       Date:  1995-11

2.  NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

Authors:  A K Malhotra; D A Pinals; H Weingartner; K Sirocco; C D Missar; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1996-05       Impact factor: 7.853

3.  Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man.

Authors:  Torsten Passie; Matthias Karst; Birgitt Wiese; Hinderk M Emrich; Udo Schneider
Journal:  Neuropsychobiology       Date:  2005-05-12       Impact factor: 2.328

4.  Reality testing and auditory hallucinations: a signal detection analysis.

Authors:  R P Bentall; P D Slade
Journal:  Br J Clin Psychol       Date:  1985-09

5.  The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action.

Authors:  C D Frith
Journal:  Psychol Med       Date:  1987-08       Impact factor: 7.723

6.  Reality monitoring and psychotic hallucinations.

Authors:  R P Bentall; G A Baker; S Havers
Journal:  Br J Clin Psychol       Date:  1991-09

7.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

8.  Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action.

Authors:  C D Frith; D J Done
Journal:  Psychol Med       Date:  1989-05       Impact factor: 7.723

9.  Reality monitoring in mania and schizophrenia. The association of thought disorder and performance.

Authors:  P D Harvey
Journal:  J Nerv Ment Dis       Date:  1985-02       Impact factor: 2.254

10.  Glutamate receptor dysfunction and schizophrenia.

Authors:  J W Olney; N B Farber
Journal:  Arch Gen Psychiatry       Date:  1995-12
View more
  14 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

3.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

4.  Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia.

Authors:  Jinsong Tang; Hannah L Morgan; Yanhui Liao; Philip R Corlett; Dong Wang; Hong Li; Yanqing Tang; Jindong Chen; Tieqiao Liu; Wei Hao; Paul C Fletcher; Xiaogang Chen
Journal:  Psychopharmacology (Berl)       Date:  2014-11-19       Impact factor: 4.530

5.  Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.

Authors:  John P Redrobe; Lisbeth Elster; Kristen Frederiksen; Christoffer Bundgaard; Inge E M de Jong; Garrick P Smith; Anne Techau Bruun; Peter H Larsen; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-29       Impact factor: 4.530

Review 6.  Acute and chronic effects of ketamine upon human memory: a review.

Authors:  Celia J A Morgan; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2006-09-28       Impact factor: 4.530

7.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

Review 8.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Authors:  Frank S Menniti; Craig W Lindsley; P Jeffrey Conn; Jayvardhan Pandit; Panayiotis Zagouras; Robert A Volkmann
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

9.  Separable forms of reality monitoring supported by anterior prefrontal cortex.

Authors:  Jon S Simons; Richard N A Henson; Sam J Gilbert; Paul C Fletcher
Journal:  J Cogn Neurosci       Date:  2008-03       Impact factor: 3.225

10.  Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers.

Authors:  A R Absalom; M Lee; D K Menon; S R Sharar; T De Smet; J Halliday; M Ogden; P Corlett; G D Honey; P C Fletcher
Journal:  Br J Anaesth       Date:  2007-03-27       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.